1. "Thoracic Oncology"
Formats
  1. Meeting Abstract (1694)
  2. Journal Article (1416)
  3. Review (80)
  4. Editorial (56)
  5. Book Section (35)
  6. Guidelines (24)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3351)
  2. Solid Tumor Oncology Division (3351)
  3. Thoracic Oncology (3351)
  4. GSK Faculty (1056)
  5. Department of Pathology and Laboratory Medicine (797)
  6. Human Oncology and Pathogenesis Program (625)

More Groups

People
  1. Mark Kris (869)
  2. Alexander Drilon (631)
  3. Gregory Riely (599)
  4. Charles Rudin (488)
  5. Marc Ladanyi (414)
  6. Matthew Hellmann (411)

More People

Years
  1. 2025 (73)
  2. 2024 (270)
  3. 2023 (272)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (692)
  2. Journal of Thoracic Oncology (513)
  3. Annals of Oncology (277)
  4. Clinical Cancer Research (156)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (769)
  2. Elsevier Inc. (734)
  3. American Association for Cancer Research (383)
  4. Oxford University Press (350)
  5. Nature Publishing Group (148)
  6. Elsevier Science, Inc. (78)

More Publishers

Results (3351)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors
    Meeting Abstract

    Li, B. T.; Lee, K. W.; Pegram, M.; Sharma, M. R.; Lee, J.; Spira, A. I.; Kang, Y. K.; Moore, K. N.; Rasco, D.; Hanna, G. J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non-small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)
    Meeting Abstract

    Smit, E. F.; Felip, E.; Uprety, D.; Nagasaka, M.; Nakagawa, K.; Paz-Ares, L.; Pacheco, J.; Li, B. T.; Planchard, D.; Baik, C. S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK plus ) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
    Meeting Abstract

    Solomon, B. J.; Drilon, A.; Lin, J. J.; Bazhenova, L.; Goto, K.; De Langen, J.; Kim, D. W.; Wolf, J.; Springfeld, C.; Popat, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
    Meeting Abstract

    Viteri, S.; Felip, E.; Griesinger, F.; Garassino, M. C.; Sakai, H.; Le, X.; Veillon, R.; Smit, E. F.; Raskin, J.; Thomas, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01
    Meeting Abstract

    Johnson, M. L.; Jänne, P. A.; Goto, Y.; Yoh, K.; Lee, S. H.; Paz-Ares, L.; Besse, B.; Novello, S.; Hayashi, H.; Kim, D. W.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Schram, A.; Goto, K.; Kim, D. W.; Hollebecque, A.; Rha, S. Y.; Nishino, K.; Duruisseaux, M.; Umemoto, K.; Park, J. O.; Leighl, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib
    Meeting Abstract

    Rolfo, C. D.; Grupp, A. M. O.; Menzel, C.; Bruns, R.; Juraeva, D.; Stroh, C.; Johne, A.; Paik, P. K.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
    Meeting Abstract

    Li, B. T.; Planchard, D.; Goto, K.; Smit, E. F.; De Langen, J.; Goto, Y.; Ninomiya, K.; Kubo, T.; Pérol, M.; Felip, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase II study of cabozantinib in patients with MET-altered lung cancers
    Meeting Abstract

    Harada, G.; Santini, F. C.; Repetti, R. W.; Chang, J.; Yang, S. R.; Lin, Y. T.; Moses, K. A.; Falcon, C.; Wilhelm, C. J.; Goldstein, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
    Meeting Abstract

    Chen, M. F.; Rosen, E.; Falcon, C.; Repetto, M.; Yang, S. R.; Chang, J.; Kris, M. G.; Rekhtman, N.; Donoghue, M.; Drilon, A.
    Annals of Oncology (2023)

    Fulltext@MSK | Save